Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies-Reference-Cited by-同舟云学术

Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies

Published:2017-11-23 Issue:12 Volume:13 Page:1237-1250
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Williamson Beth¹,Riley Robert J.¹

Affiliation:

1. Drug Metabolism and Pharmacokinetics, Evotec, Abingdon, UK

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2017.1404028

Reference59 articles.

1. Clinical development success rates for investigational drugs

2. An analysis of the attrition of drug candidates from four major pharmaceutical companies

3. Chung TDY, Terry DB, Smith LH. In vitro and in vivo assessment of ADME and PK properties during lead selection and lead optimization – Guidelines, Benchmarks and Rules of Thumb. 2015 Sep 9. In: Sittampalam GS, Coussens NP, Brimacombe K, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004- Available from: https://www.ncbi.nlm.nih.gov/books/NBK326710/

4. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Interactions: Mechanisms, Assessment and Management Strategies;Journal of Young Pharmacists;2024-08-23

2. Research Landscape of Physiologically Based Pharmacokinetic Model Utilization in Different Fields: A Bibliometric Analysis (1999–2023);Pharmaceutical Research;2024-02-21

3. Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3;Pharmacology Research & Perspectives;2023-02-22

4. Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward;Biopharmaceutics & Drug Disposition;2022-12-14

5. Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development;Expert Opinion on Drug Metabolism & Toxicology;2022-10-03